 | Up a level |
Lämmle, Bernhard; Vanhoorelbeke, Karen; Kremer Hovinga, Johanna A.; Knöbl, Paul (2024). 100 Years of Thrombotic Thrombocytopenic Purpura: A Story of Death and Life. Hämostaseologie, 44(1), pp. 59-73. Thieme 10.1055/a-2223-9484
Scully, Marie; de la Rubia, Javier; Pavenski, Katerina; Metjian, Ara; Knöbl, Paul; Peyvandi, Flora; Cataland, Spero; Coppo, Paul; Kremer Hovinga, Johanna A; Minkue Mi Edou, Jessica; De Passos Sousa, Rui; Callewaert, Filip; Gunawardena, Sriya; Lin, Julie (2022). Long-term follow-up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post-HERCULES study. Journal of thrombosis and haemostasis, 20(12), pp. 2810-2822. Wiley-Blackwell 10.1111/jth.15892
Tarasco, Erika; Bütikofer, Lukas; Friedman, Kenneth D; George, James N; Hrachovinova, Ingrid V; Knöbl, Paul; Matsumoto, Masanori; von Krogh, Anne Sophie; Aebi-Huber, Isabella; Cermakova, Zuzana; Górska-Kosicka, Magdalena; Jalowiec, Katarzyna A; Largiadèr, Carlo R; Prohaszka, Zoltan; Sinkovits, György; Windyga, Jerzy; Lämmle, Bernhard; Kremer Hovinga, Johanna A (2021). Annual Incidence and Severity of Acute Episodes in Hereditary Thrombotic Thrombocytopenic Purpura. Blood, 137(25), pp. 3563-3575. American Society of Hematology 10.1182/blood.2020009801
Scully, Marie; Cataland, Spero R; Peyvandi, Flora; Coppo, Paul; Knöbl, Paul; Kremer Hovinga, Johanna A.; Metjian, Ara; de la Rubia, Javier; Pavenski, Katerina; Callewaert, Filip; Biswas, Debjit; De Winter, Hilde; Zeldin, Robert K (2019). Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura. The New England journal of medicine, 380(4), pp. 335-346. Massachusetts Medical Society 10.1056/NEJMoa1806311
Scully, Marie; Knöbl, Paul; Kentouche, Karim; Rice, Lawrence; Windyga, Jerzy; Schneppenheim, Reinhard; Kremer Hovinga, Johanna Anna; Kajiwara, Michiko; Fujimura, Yoshihiro; Maggiore, Caterina; Doralt, Jennifer; Hibbard, Christopher; Martell, Leah; Ewenstein, Bruce (2017). A recombinant human ADAMTS-13: first-in-human study evaluating pharmacokinetics, safety and tolerability in cTTP patients. Blood, 130(19), pp. 2055-2063. American Society of Hematology 10.1182/blood-2017-06-788026
Peyvandi, Flora; Scully, Marie; Kremer Hovinga, Johanna Anna; Cataland, Spero; Knöbl, Paul; Wu, Haifeng; Artoni, Andrea; Westwood, John-Paul; Mansouri Taleghani, Magnus; Jilma, Bernd; Callewaert, Filip; Ulrichts, Hans; Duby, Christian; Tersago, Dominique (2016). Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. New England journal of medicine NEJM, 374(6), pp. 511-522. Massachusetts Medical Society MMS 10.1056/NEJMoa1505533
Ferrari, Silvia; Palavra, Kristina; Gruber, Bernadette; Kremer Hovinga, Johanna Anna; Knöbl, Paul; Caron, Claudine; Cromwell, Caroline; Aledort, Louis; Plaimauer, Barbara; Turecek, Peter L.; Rottensteiner, Hanspeter; Scheiflinger, Friedrich (2014). Persistence of circulating ADAMTS13-specific immune complexes in patients with acquired thrombotic thrombocytopenic purpura. Haematologica - the hematology journal, 99(4), pp. 779-787. Ferrata-Storti Foundation 10.3324/haematol.2013.094151
Tiede, Andreas; Huth-Kühne, Angela; Oldenburg, Johannes; Grossmann, Ralf; Geisen, Ulrich; Krause, Manuela; Brand, Brigit; Alberio, Lorenzo; Klamroth, Robert; Spannagl, Michael; Knöbl, Paul (2009). Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland. Annals of hematology, 88(4), pp. 365-70. Berlin: Springer 10.1007/s00277-008-0665-7
